WebbFor applicable clinical trials with a Primary Completion Date on or after January 18, 2024, the final rule in 42 CFR 11.44(c) also provides for the delayed submission of results information under certain conditions with certification if the responsible party is seeking initial approval, licensure, or clearance for the studied product. Webbeffective date of January 2, 2013 The Pfizer SOP uses the PCD as the starting point for calculating the time to submission • The Primary Completion Dateis defined by the NIH as the following: • The Primary Completion Date, the PCD, is the date that the final subject was examined or received an intervention for the purposes
NIH Policy on Dissemination of NIH-Funded Clinical Trial Information
Webb12 apr. 2024 · If the required registration or results reporting information is overdue by more than 30 days after enrollment of first participant for the registration or by more than 12 months after the trial’s actual primary completion date for results reporting at the time of (RPPR) submission, grant recipients will receive an error, and if the requirements are … Webb29 okt. 2024 · We queried ClinicalTrials.gov 25 with 2 separate searches, using the terms “acute myeloid leukemia” and “acute lymphoid leukemia,” respectively, with start and primary completion dates between January 1, 2002, and December 31, 2024. o\u0027reilly auto parts troy il
eCFR :: 42 CFR Part 11 -- Clinical Trials Registration and Results ...
Webb18 nov. 2024 · Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed … WebbCompletion Date (See Primary Completion Date data element on ClinicalTrials.gov) Other changes or updates to the record, such as protocol amendments, must be made … Webb18 dec. 2024 · Of these, 7 (tremelimumab, spartalizumab, BCD-100, omburtamab, mirvetuximab soravtansine, trastuzumab duocarmazine, and depatuxizumab mafodotin) are being evaluated in clinical studies with primary completion dates in late 2024 and in 2024, and are thus 'antibodies to watch'. We look forward to documenting progress … roddie bryan cell phone